Home » Newsletters » BioWorld Asia

BioWorld Asia

June 2, 1999

View Archived Issues

Cortecs' Macritonin Fails; Stock Drops One-Fourth

Dolly's Shorter Telomeres Mean Brief Culture Time Best In Therapy Research

RPR's p53 Gene Therapy Strong In Phase II Trials

CGL's Surface-Protein Work Boosted By #4M Financing

Genset, Alghne Sign Deal For Alzheimer's Research

AnorMED's HIV Treatment Moves Into Phase II Study

Thallia Plans Launch Of Circulatory Product

CAT Ending Program For Obesity Antibody

Appligene Oncor Says Sales Up, Losses Lower

Oxagen, Lynx Partnering In Disease-Linked SNPs

Cerep Reports Revenues, Enters Deal With Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...